O	0	6	Pooled
O	7	15	analysis
O	16	18	of
O	19	22	two
O	23	33	randomized
O	33	34	,
O	35	41	double
O	41	42	-
O	42	47	blind
O	48	54	trials
O	55	64	comparing
O	65	73	proposed
O	74	84	biosimilar
B-intervention	85	87	LA
I-intervention	87	88	-
I-intervention	88	94	EP2006
O	95	99	with
B-control	100	109	reference
I-control	110	123	pegfilgrastim
O	124	126	in
O	127	133	breast
O	134	140	cancer
O	140	141	.

O	142	151	Following
O	152	155	the
O	156	166	functional
O	167	170	and
O	171	186	physicochemical
O	187	203	characterization
O	204	206	of
O	207	208	a
O	209	217	proposed
O	218	228	biosimilar
O	228	229	,
O	230	241	comparative
O	242	250	clinical
O	251	258	studies
O	259	263	help
O	264	266	to
O	267	274	confirm
O	275	288	biosimilarity
O	289	291	by
O	292	305	demonstrating
O	306	313	similar
O	314	320	safety
O	321	324	and
O	325	333	efficacy
O	334	336	to
O	337	340	the
O	341	350	reference
O	351	358	product
O	359	361	in
O	362	363	a
O	364	373	sensitive
O	374	381	patient
O	382	392	population
O	392	393	.

O	394	396	LA
O	396	397	-
O	397	403	EP2006
O	404	406	is
O	407	408	a
O	409	417	proposed
O	418	428	biosimilar
O	429	433	that
O	434	437	has
O	438	442	been
O	443	452	developed
O	453	456	for
O	457	470	pegfilgrastim
O	470	471	,
O	472	473	a
O	474	478	long
O	478	479	-
O	479	485	acting
O	486	490	form
O	491	493	of
O	494	505	granulocyte
O	506	512	colony
O	512	513	-
O	513	524	stimulating
O	525	531	factor
O	532	535	for
O	536	539	the
O	540	550	prevention
O	551	553	of
O	554	565	neutropenia
O	565	566	.

O	567	570	The
O	571	578	current
O	579	587	analysis
O	588	595	reports
O	596	600	data
O	601	607	pooled
O	608	612	from
O	613	616	two
O	617	628	independent
O	628	629	,
O	630	643	multinational
O	643	644	,
O	645	656	prospective
O	656	657	,
O	658	668	randomized
O	668	669	,
O	670	680	controlled
O	680	681	,
O	682	688	double
O	688	689	-
O	689	694	blind
O	695	700	phase
O	701	704	III
O	705	712	studies
O	713	715	of
O	716	723	similar
O	724	730	design
O	731	740	comparing
O	741	744	the
O	745	751	safety
O	752	755	and
O	756	764	efficacy
O	765	767	of
O	768	777	reference
O	778	791	pegfilgrastim
O	792	796	with
O	797	799	LA
O	799	800	-
O	800	806	EP2006
O	807	809	in
B-eligibility	810	818	patients
I-eligibility	819	823	with
I-eligibility	824	830	breast
I-eligibility	831	837	cancer
I-eligibility	838	847	receiving
I-eligibility	848	858	myelotoxic
I-eligibility	859	860	(
I-eligibility	860	863	neo
I-eligibility	863	864	)
I-eligibility	864	872	adjuvant
I-eligibility	873	876	TAC
I-eligibility	877	878	(
I-eligibility	878	887	docetaxel
I-eligibility	887	888	,
I-eligibility	889	900	doxorubicin
I-eligibility	900	901	,
I-eligibility	902	905	and
I-eligibility	906	922	cyclophosphamide
I-eligibility	922	923	)
I-eligibility	924	936	chemotherapy
I-eligibility	937	940	and
I-eligibility	941	950	requiring
I-eligibility	951	962	granulocyte
I-eligibility	963	969	colony
I-eligibility	969	970	-
I-eligibility	970	981	stimulating
I-eligibility	982	988	factor
O	988	989	.

O	990	991	A
O	992	997	total
O	998	1000	of
B-total-participants	1001	1004	624
O	1005	1013	patients
O	1014	1018	were
O	1019	1029	randomized
O	1030	1032	in
O	1033	1036	the
O	1037	1044	PROTECT
O	1044	1045	-
O	1045	1046	1
O	1047	1050	and
O	1051	1058	PROTECT
O	1058	1059	-
O	1059	1060	2
O	1061	1068	studies
O	1069	1070	(
O	1070	1081	NCT01735175
O	1081	1082	;
O	1083	1094	NCT01516736
O	1094	1095	)
O	1096	1097	(
O	1097	1099	LA
O	1099	1100	-
O	1100	1106	EP2006
O	1106	1107	:
O	1108	1109	n
O	1110	1111	=
B-intervention-participants	1112	1115	314
O	1115	1116	;
O	1117	1126	reference
O	1126	1127	:
O	1128	1129	n
O	1130	1131	=
B-control-participants	1132	1135	310
O	1135	1136	)
O	1136	1137	.

O	1138	1146	Baseline
O	1147	1162	characteristics
O	1163	1165	of
O	1166	1174	patients
O	1175	1179	were
O	1180	1184	well
O	1185	1193	balanced
O	1194	1200	across
O	1201	1210	treatment
O	1211	1217	groups
O	1217	1218	.

O	1219	1222	The
O	1223	1230	primary
O	1231	1234	end
O	1235	1240	point
O	1240	1241	,
B-outcome	1242	1246	mean
I-outcome	1247	1255	duration
I-outcome	1256	1258	of
I-outcome	1259	1265	severe
I-outcome	1266	1277	neutropenia
O	1278	1280	in
O	1281	1284	the
O	1285	1290	first
O	1291	1303	chemotherapy
O	1304	1309	cycle
O	1310	1313	was
O	1314	1321	similar
O	1322	1324	in
O	1325	1329	both
O	1330	1333	the
O	1334	1336	LA
O	1336	1337	-
O	1337	1343	EP2006
O	1344	1347	and
O	1348	1357	reference
O	1358	1364	groups
O	1365	1366	(
B-iv-cont-mean	1366	1367	1
I-iv-cont-mean	1367	1368	.
I-iv-cont-mean	1368	1370	05
O	1371	1372	±
B-iv-cont-sd	1373	1374	1
I-iv-cont-sd	1374	1375	.
I-iv-cont-sd	1375	1378	055
I-iv-cont-sd	1379	1383	days
O	1384	1390	versus
B-cv-cont-mean	1391	1392	1
I-cv-cont-mean	1392	1393	.
I-cv-cont-mean	1393	1395	01
O	1396	1397	±
B-cv-cont-sd	1398	1399	0
I-cv-cont-sd	1399	1400	.
I-cv-cont-sd	1400	1403	958
I-cv-cont-sd	1404	1408	days
O	1408	1409	)
O	1409	1410	,
O	1411	1415	with
O	1416	1417	a
O	1418	1427	treatment
O	1428	1438	difference
O	1439	1441	of
O	1442	1443	-
O	1444	1445	0
O	1445	1446	.
O	1446	1448	04
O	1449	1453	days
O	1454	1455	[
O	1455	1457	95
O	1457	1458	%
O	1459	1469	confidence
O	1470	1478	interval
O	1479	1480	(
O	1480	1482	CI
O	1482	1483	)
O	1483	1484	:
O	1485	1486	-
O	1486	1487	0
O	1487	1488	.
O	1488	1490	19
O	1491	1493	to
O	1494	1495	0
O	1495	1496	.
O	1496	1498	11
O	1498	1499	]
O	1500	1504	that
O	1505	1508	met
O	1509	1512	the
O	1513	1524	equivalence
O	1525	1533	criteria
O	1534	1535	(
O	1535	1538	the
O	1539	1541	95
O	1541	1542	%
O	1543	1545	CI
O	1546	1550	were
O	1551	1557	within
O	1558	1561	the
O	1562	1569	defined
O	1570	1576	margin
O	1577	1579	of
O	1580	1581	±
O	1581	1582	1
O	1583	1586	day
O	1586	1587	)
O	1587	1588	.

O	1589	1598	Secondary
O	1599	1602	end
O	1603	1609	points
O	1609	1610	,
O	1611	1615	such
O	1616	1618	as
O	1619	1622	the
B-outcome	1623	1628	nadir
I-outcome	1629	1631	of
I-outcome	1632	1640	absolute
I-outcome	1641	1651	neutrophil
I-outcome	1652	1657	count
O	1658	1661	and
O	1662	1665	the
B-outcome	1666	1675	incidence
I-outcome	1676	1678	of
I-outcome	1679	1686	febrile
I-outcome	1687	1698	neutropenia
O	1698	1699	,
O	1700	1704	were
O	1705	1709	also
O	1710	1717	similar
O	1718	1725	between
O	1726	1728	LA
O	1728	1729	-
O	1729	1735	EP2006
O	1736	1739	and
O	1740	1749	reference
O	1750	1763	pegfilgrastim
O	1763	1764	.

O	1765	1768	The
B-outcome	1769	1775	safety
I-outcome	1776	1779	and
I-outcome	1780	1792	tolerability
I-outcome	1793	1800	profile
O	1801	1803	of
O	1804	1806	LA
O	1806	1807	-
O	1807	1813	EP2006
O	1814	1817	was
O	1818	1825	similar
O	1826	1828	to
O	1829	1833	that
O	1834	1842	observed
O	1843	1847	with
O	1848	1857	reference
O	1858	1871	pegfilgrastim
O	1871	1872	,
O	1873	1876	and
O	1877	1882	there
O	1883	1887	were
O	1888	1890	no
O	1891	1898	reports
O	1899	1901	of
O	1902	1914	neutralizing
O	1915	1925	antibodies
O	1925	1926	.

O	1927	1931	This
O	1932	1938	pooled
O	1939	1947	analysis
O	1948	1956	confirms
O	1956	1957	,
O	1958	1960	as
O	1961	1962	a
O	1963	1967	part
O	1968	1970	of
O	1971	1979	totality
O	1980	1982	of
O	1983	1991	evidence
O	1992	2000	approach
O	2000	2001	,
O	2002	2006	that
O	2007	2010	the
O	2011	2019	proposed
O	2020	2030	biosimilar
O	2031	2044	pegfilgrastim
O	2045	2047	LA
O	2047	2048	-
O	2048	2054	EP2006
O	2055	2058	has
O	2059	2060	a
O	2061	2071	comparable
O	2072	2080	efficacy
O	2081	2084	and
O	2085	2091	safety
O	2092	2099	profile
O	2100	2102	to
O	2103	2112	reference
O	2113	2126	pegfilgrastim
O	2127	2129	in
O	2130	2138	patients
O	2139	2143	with
O	2144	2150	breast
O	2151	2157	cancer
O	2158	2167	receiving
O	2168	2171	TAC
O	2172	2184	chemotherapy
O	2184	2185	.

O	2186	2197	NCT01735175
O	2198	2201	and
O	2202	2213	NCT01516736
O	2213	2214	.
